EZH2遺伝子変異を有する再発性または難治性B細胞非ホジキンリンパ腫患者におけるタゼメトスタットの有効性に関する研究
基本情報
- NCT ID
- NCT03456726
- ステータス
- 完了
- 試験のフェーズ
- 第2相
- 試験タイプ
- 介入
- 目標被験者数
- 20
- 治験依頼者名
- Eisai Inc.
概要
This is a multicenter, open-label, Phase 2 study to assess the efficacy and safety of tazemetostat in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) with EZH2 gene mutation.
対象疾患
介入
依頼者（Sponsor）
実施施設 (28)
1008 Eisai Trial Site
Kyoto, Japan
1001 Eisai Trial Site
Chuo-ku, Tokyo, Japan
1010 Eisai Trial Site
Chiba, Japan
1002 Eisai Trial Site
Isehara, Kanagawa, Japan
1003 Eisai Trial Site
Kyoto, Japan
1009 Eisai Trial Site
Okayama, Japan
1015 Eisai Trial Site
Osaka, Japan
1024 Eisai Trial Site
Kumamoto, Japan
1012 Eisai Trial Site
Fukuoka, Japan
1019 Eisai Trial Site
Kobe, Hyōgo, Japan
1027 Eisai Trial Site
Suntou-gun, Shizuoka, Japan
1025 Eisai Trial Site
Koto-ku, Tokyo, Japan
1020 Eisai Trial Site
Ōta, Gunma, Japan
1028 Eisai Trial Site
Yokohama, Kanagawa, Japan
1005 Eisai Trial Site
Tsukuba, Ibaraki, Japan
1013 Eisai Trial Site
Sayama, Osaka, Japan
1018 Eisai Trial Site
Yamagata, Japan
1022 Eisai Trial Site
Aomori, Japan
1023 Eisai Trial Site
Nagasaki, Japan
1026 Eisai Trial Site
Bunkyo-ku, Tokyo, Japan
1004 Eisai Trial Site
Nagoya, Aichi-ken, Japan
1006 Eisai Trial Site
Suita, Osaka, Japan
1017 Eisai Trial Site
Minato-ku, Tokyo, Japan
1021 Eisai Trial Site
Sendai, Miyagi, Japan
1007 Eisai Trial Site
Sapporo, Hokkaido, Japan
1016 Eisai Trial Site
Fukuoka, Japan
1011 Eisai Trial Site
Hiroshima, Japan
1029 Eisai Trial Site
Nagoya, Aichi-ken, Japan